432 related articles for article (PubMed ID: 30576770)
1. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
2. Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
Li JJ; Chen WL; Wang JY; Hu QW; Sun ZP; Zhang S; Liu S; Han XH
Acta Pharmacol Sin; 2017 Oct; 38(10):1369-1380. PubMed ID: 28414206
[TBL] [Abstract][Full Text] [Related]
3. Anti-metastatic effect and mechanisms of Wenshen Zhuanggu Formula in human breast cancer cells.
Han XH; Wang CL; Xie Y; Ma J; Zhang XH; Hu QW; Lin G; Liu S; Lu JG
J Ethnopharmacol; 2015 Mar; 162():39-46. PubMed ID: 25554638
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of six coumarins in normal and breast cancer bone-metastatic mice after oral administration of Wenshen Zhuanggu Formula.
Chen W; Li J; Sun Z; Wu C; Ma J; Wang J; Liu S; Han X
J Ethnopharmacol; 2018 Oct; 224():36-44. PubMed ID: 29803570
[TBL] [Abstract][Full Text] [Related]
5. WSZG inhibits BMSC-induced EMT and bone metastasis in breast cancer by regulating TGF-β1/Smads signaling.
Ma J; Li J; Wang Y; Chen W; Zheng P; Chen Y; Sun Z; Liu J; Zhou Y; Wang J; Liu S; Han X
Biomed Pharmacother; 2020 Jan; 121():109617. PubMed ID: 31810139
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells.
Sethi N; Dai X; Winter CG; Kang Y
Cancer Cell; 2011 Feb; 19(2):192-205. PubMed ID: 21295524
[TBL] [Abstract][Full Text] [Related]
7. Brucine inhibits bone metastasis of breast cancer cells by suppressing Jagged1/Notch1 signaling pathways.
Hu KF; Kong XY; Zhong MC; Wan HY; Lin N; Pei XH
Chin J Integr Med; 2017 Feb; 23(2):110-116. PubMed ID: 28035539
[TBL] [Abstract][Full Text] [Related]
8. Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis.
Zhang Z; Wang H; Ikeda S; Fahey F; Bielenberg D; Smits P; Hauschka PV
Am J Pathol; 2010 Sep; 177(3):1459-69. PubMed ID: 20651241
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of Bone Homeostasis by DLL1-Mediated Notch Signaling.
Muguruma Y; Hozumi K; Warita H; Yahata T; Uno T; Ito M; Ando K
J Cell Physiol; 2017 Sep; 232(9):2569-2580. PubMed ID: 27735989
[TBL] [Abstract][Full Text] [Related]
10. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
[TBL] [Abstract][Full Text] [Related]
11. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
Zong JC; Wang X; Zhou X; Wang C; Chen L; Yin LJ; He BC; Deng ZL
Oncol Rep; 2016 Feb; 35(2):739-48. PubMed ID: 26573960
[TBL] [Abstract][Full Text] [Related]
12. The Notch Ligand Jagged1 Regulates the Osteoblastic Lineage by Maintaining the Osteoprogenitor Pool.
Lawal RA; Zhou X; Batey K; Hoffman CM; Georger MA; Radtke F; Hilton MJ; Xing L; Frisch BJ; Calvi LM
J Bone Miner Res; 2017 Jun; 32(6):1320-1331. PubMed ID: 28277610
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Yin JJ; Selander K; Chirgwin JM; Dallas M; Grubbs BG; Wieser R; Massagué J; Mundy GR; Guise TA
J Clin Invest; 1999 Jan; 103(2):197-206. PubMed ID: 9916131
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.
Zheng H; Bae Y; Kasimir-Bauer S; Tang R; Chen J; Ren G; Yuan M; Esposito M; Li W; Wei Y; Shen M; Zhang L; Tupitsyn N; Pantel K; King C; Sun J; Moriguchi J; Jun HT; Coxon A; Lee B; Kang Y
Cancer Cell; 2017 Dec; 32(6):731-747.e6. PubMed ID: 29232552
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction.
Tan CC; Li GX; Tan LD; Du X; Li XQ; He R; Wang QS; Feng YM
Oncotarget; 2016 Nov; 7(48):79688-79705. PubMed ID: 27806311
[TBL] [Abstract][Full Text] [Related]
17. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
19. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis.
Meng X; Vander Ark A; Lee P; Hostetter G; Bhowmick NA; Matrisian LM; Williams BO; Miranti CK; Li X
Oncogene; 2016 May; 35(18):2370-8. PubMed ID: 26279296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
